Unlike other types of breast cancer such as ER+ or PR+ breast cancer, due to a lack of effective targeted therapies, there are limited treatment options for TNBC cases, as well as refractory breast tumors, which are resistant to currently available therapies [38]. Here, ESR1 is linked to breast carcinoma.